Free Trial

Spero Therapeutics (SPRO) News Today

Spero Therapeutics logo
$0.91 +0.08 (+9.00%)
As of 01/17/2025 04:00 PM Eastern
Spero Therapeutics Inc SPRO
Spero Therapeutics announces interim leadership changes
Spero Therapeutics, Inc. stock logo
Spero Therapeutics (NASDAQ:SPRO) Stock Passes Below Two Hundred Day Moving Average - Time to Sell?
Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Below 200-Day Moving Average - What's Next?
Spero Therapeutics (SPRO) was downgraded to a Hold Rating at Evercore ISI
Spero Therapeutics, Inc. stock logo
Evercore ISI Downgrades Spero Therapeutics (NASDAQ:SPRO) to In-Line
Evercore ISI downgraded Spero Therapeutics from an "outperform" rating to an "in-line" rating and set a $5.00 target price on the stock. in a research report on Friday.
Spero Therapeutics, Inc. stock logo
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average - Should You Sell?
Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Below 200-Day Moving Average - What's Next?
Spero Therapeutics, Inc. stock logo
HC Wainwright Issues Pessimistic Estimate for SPRO Earnings
Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) - Research analysts at HC Wainwright lowered their FY2024 earnings estimates for Spero Therapeutics in a report released on Monday, December 2nd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of
Spero Therapeutics downgraded to Hold from Buy at TD Cowen
Spero Therapeutics, Inc. stock logo
Spero Therapeutics (NASDAQ:SPRO) Receives Hold Rating from TD Cowen
TD Cowen restated a "hold" rating on shares of Spero Therapeutics in a research note on Monday.
TD Cowen downgrades Spero Therapeutics (SPRO) to a Hold
Spero Therapeutics: Strategic Shift and Earnings Update
Spero Therapeutics, Inc. stock logo
Spero Therapeutics' (SPRO) Overweight Rating Reaffirmed at Cantor Fitzgerald
Cantor Fitzgerald reiterated an "overweight" rating on shares of Spero Therapeutics in a research note on Friday.
Spero Therapeutics, Inc. stock logo
Spero Therapeutics (SPRO) Set to Announce Earnings on Thursday
Spero Therapeutics (NASDAQ:SPRO) will be releasing earnings after the market closes on Thursday, November 14, Zacks reports.
Spero Therapeutics, Inc. stock logo
Q3 EPS Estimate for Spero Therapeutics Boosted by Analyst
Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) - Equities research analysts at HC Wainwright upped their Q3 2024 earnings per share (EPS) estimates for Spero Therapeutics in a research report issued to clients and investors on Monday, November 4th. HC Wainwright analyst R. Selvaraju now for
Spero Therapeutics, Inc. stock logo
HC Wainwright Lowers Spero Therapeutics (NASDAQ:SPRO) Price Target to $5.00
HC Wainwright cut their price objective on Spero Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a research note on Monday.
Spero suspends development of SPR720, to reduce workforce by 39%
Spero Therapeutics Restructures Focus on Key R&D Projects
Spero Therapeutics, Inc. stock logo
Spero Therapeutics (NASDAQ:SPRO) Shares Pass Below 200 Day Moving Average - Here's Why
Spero Therapeutics (NASDAQ:SPRO) Shares Pass Below 200 Day Moving Average - Should You Sell?
Spero Therapeutics, Inc. stock logo
Spero Therapeutics (NASDAQ:SPRO) Shares Pass Below Two Hundred Day Moving Average of $1.46
Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below Two Hundred Day Moving Average of $1.46
Spero Therapeutics, Inc. stock logo
Spero Therapeutics (NASDAQ:SPRO) Shares Pass Below 200 Day Moving Average of $1.48
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below 200 Day Moving Average of $1.48
Spero Therapeutics, Inc. stock logo
Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below 200 Day Moving Average of $1.49
Spero Therapeutics (NASDAQ:SPRO) Share Price Crosses Below Two Hundred Day Moving Average of $1.49
Spero Therapeutics, Inc. stock logo
HC Wainwright Weighs in on Spero Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:SPRO)
Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for Spero Therapeutics in a research report issued to clients and investors on Tuesday, August 6th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn (
Get Spero Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.

SPRO Media Mentions By Week

SPRO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SPRO
News Sentiment

0.43

0.57

Average
Medical
News Sentiment

SPRO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SPRO Articles
This Week

2

2

SPRO Articles
Average Week

Get Spero Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:SPRO) was last updated on 1/18/2025 by MarketBeat.com Staff
From Our Partners